Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service

Ambys Medicines Announces Presentation on Novel Liver Cell Therapy Platform for Severe Liver Diseases, and Opening of its cGMP Cell Therapy Manufacturing Facility

Ambys Medicines, a cell and gene therapy company focused on transforming the treatment of severe liver disease by unlocking the full potential of hepatocyte transplantation, today announced their presentation highlighting the development of a first-of-its-kind bioreactor manufacturing platform. The data presented demonstrate Ambys' ability to expand mature, fully functional human hepatocytes while maintaining biological function. This is a critical step towards Ambys' goal of providing an off-the-shelf treatment capable of revolutionizing care for patients with severe liver disease. The data were presented at the IXA-CTRMS-2021 Virtual Congress on September 25, 2021.

The company also announced the opening of a state-of-the-art manufacturing facility in South San Francisco, Calif., which will be outfitted for industrial-scale expansion and production of hepatocytes under current Good Manufacturing Practices (cGMP). This unique facility will support the clinical development and early commercialization of Ambys' lead allogeneic program as well as the company's follow-on programs, enabling the first mature, human hepatocyte cell therapies for the treatment of severe liver disease. With Ambys' breakthrough technology, the promise of hepatocyte transplantation may finally be realized, extending the lives of those with no treatment options and reducing the need for liver transplants.

??"The concept of hepatocyte transplantation with donor cells has been explored in academic settings for over 20 years," said Ron Park, M.D., CEO of Ambys Medicines. "These past efforts showed that mature hepatocytes were active and that the approach was safe, but further progress has been limited by the inability to generate adequate quantities of high-quality hepatocytes sufficient to drive clinical benefit. We believe that Ambys' technology will facilitate broad use of hepatocyte transplantation to significantly alter the treatment paradigm for patients with severe liver diseases, and our data presented this week validate this strategy. Now, with the opening of our GMP facility, we can begin the process to scale hepatocyte expansion to the levels needed to support our clinical development efforts."

In the presentation, "Development of a novel rat bioreactor to facilitate the manufacture of human hepatocyte cell therapies for treating patients with severe liver diseases," Ambys demonstrated that donor human hepatocytes expanded in their proprietary in vivo bioreactor, robustly engrafted in diseased animal models, and restored liver function in those models. Moreover, these human cells maintained, or even enhanced, their hepatocyte phenotype and durability in in vitro testing.

"These data demonstrate our fundamental ability to produce high-quality, mature human hepatocytes at quantities needed to support our clinical development and early commercialization efforts," said Alan Smith, Ph.D., Chief Technology Officer. "Our lead program, AMI-918, an allogeneic, off-the-shelf investigational cell therapy aimed at providing functional liver support in the acute setting, is an important advancement in transforming the treatment of severe liver disease."

Liver diseases are one of the most underserved areas of medicine. More than 1.3 million people worldwide die each year from liver diseases, and the prevalence continues to grow. If successful, the company's platform of cell therapies can address a spectrum of unmet needs, including the more intractable long-term progression of severe liver disease and certain genetically driven liver diseases.

"Ambys' bioreactor is genetically modified to engraft and preferentially proliferate human hepatocytes," said Michael Holmes, Ph.D., Chief Scientific Officer. "This proprietary system amplifies the quantity of human hepatocytes and allows for greater consistency in the quality of cells. Industrializing this process will allow us to break through the barriers that have stalled hepatocyte transplantation and bring life-saving treatments to people affected by severe liver disease."

Ambys expects to start production in this manufacturing facility in mid-2022 and file its first investigational new drug application later that year.

About AMI-918

Liver diseases remain one of the most underserved areas of modern medicine. Despite progress with a few diseases, severe liver diseases are not effectively addressed. Until now, the field has had to choose between promoting hepatocyte proliferation or function. Ambys' proprietary in vivo bioreactor has solved for both expansion and function, generating the first and only mature, off-the-shelf hepatocyte cell therapy that will be available at therapeutic doses. AMI-918 is an allogeneic, off-the-shelf hepatocyte cell therapy for the potential on-demand treatment of patients in acute settings, in conjunction with immunosuppression.

About Ambys Medicines

Ambys Medicines is a cell and gene therapy company focused on unlocking the full potential of hepatocyte transplantation and transforming the treatment of severe liver disease. Ambys' proprietary cell therapy platform potentially solves the supply constraints that have hindered progress, catalyzing the field and fundamentally transforming the approach to treating severe liver disease. Our lead program, AMI-918, and future engineered hepatocyte cell therapies are being developed across the spectrum of severe liver disease, including those of acquired and genetic origins. Visit us at ambys.com and follow us on Twitter, LinkedIn, and Instagram.

These press releases may also interest you

at 19:29
Global advertising and marketing agency Channel Bakers announced it has partnered with Skai, a leading commerce intelligence platform, to expand the agency's suite of eCommerce solutions. Agency CEO and Founder Joshua Kreitzer said the Skai...

at 19:00
Skypod is pleased to announce their support of Breast Cancer Awareness Month alongside The National Breast Cancer Foundation with a $100 credit donation to all those who have been recently diagnosed with or who have survived breast cancer. This past...

at 19:00
Meeami Technologies (Meeami®), a pioneer and leader in audio AI, noise cancellation, speaker ID and audio analytics software, today announced that its flag ship ClearVoice noise cancellation technology is available for Contact Center agents on...

at 18:55
Blume Global, the leading provider of supply chain execution and visibility solutions, is proud to be the first to deliver logistics execution and supply chain visibility solutions completely native to Google Cloud Platform. Customers that use...

at 18:54
Apollo Career Center ("Apollo"), an adult education center located in Allen County, Ohio, recently announced that it identified and addressed a data security incident. Apollo immediately began to investigate, a cybersecurity firm was engaged, and...

at 18:49
Sprout Mortgage is strengthening its robust line of automation tools for a fully digital mortgage experience with the release of its third originator-focused mortgage tool. Sprout will unveil iAnalyze, the first non-QM bank statement analyzer tool of...

News published on 27 september 2021 at 09:05 and distributed by: